New development of pharmacotherapy--physiological basis and future possibility

Masakazu Ichinose

Research output: Contribution to journalReview articlepeer-review


In COPD management, currently available treatments improve the quality of life (QOL) of the patients. According to the international and Japanese guidelines, long-acting bronchodilators are central to the management of COPD. Recently developed long-acting anti -cholinergic agent and beta2-agonists show remarkable effects on COPD subjects compared with short-acting agents. The physiological explanation of the efficacy of long-acting bronchodilators seems to be due to the pharmacological volume reduction via airway dilation. In future, we need COPD specific anti-inflammatory agents, including histone deacetylase (HDAC) activator.

Original languageEnglish
Pages (from-to)689-695
Number of pages7
JournalNippon rinsho. Japanese journal of clinical medicine
Issue number4
Publication statusPublished - 2007 Apr
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'New development of pharmacotherapy--physiological basis and future possibility'. Together they form a unique fingerprint.

Cite this